Can Benadryl and Montelukast Be Taken Together?
Yes, diphenhydramine (Benadryl) and montelukast can be safely taken together—there are no known drug interactions between these medications, and combination therapy with antihistamines and leukotriene receptor antagonists is explicitly supported in clinical guidelines for allergic conditions.
Safety Profile of Concurrent Use
The combination of diphenhydramine and montelukast poses no pharmacologic contraindications:
No drug-drug interactions exist between these agents based on montelukast's metabolic profile. Montelukast is metabolized primarily by CYP3A4 and CYP2C9, while diphenhydramine does not significantly interact with these pathways 1.
FDA labeling for montelukast explicitly states it "was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions," including antihistamines 1.
Guideline-supported combination: The Journal of Allergy and Clinical Immunology practice parameters state that "the combination of an antihistamine and LTRAs is superior to either therapy when given alone" for allergic rhinitis 2.
Clinical Context for Combined Use
For Allergic Rhinitis
- Combination therapy provides additive benefit over monotherapy for nasal symptoms and quality of life in allergic rhinitis 2.
- This approach is particularly useful for patients unresponsive to intranasal corticosteroids or when corticosteroids are contraindicated 2.
- Recent meta-analysis confirms that montelukast-antihistamine combinations significantly improve daytime nasal symptoms, nighttime symptoms, and quality of life scores compared to antihistamine alone 3.
For Asthma with Allergic Rhinitis
- Dual benefit for upper and lower airways: When patients have both asthma and allergic rhinitis (occurring in up to 40% of cases), montelukast may be considered to benefit both conditions 2.
- The NAEPP guidelines list leukotriene receptor antagonists as alternative therapy that can be combined with other agents in stepwise asthma management 4.
For Anaphylaxis
- In emergency settings, diphenhydramine is second-line therapy (after epinephrine) and can be administered alongside other medications including those for bronchospasm 5.
Important Caveats
Sedation Risk with Diphenhydramine
- Diphenhydramine causes significant sedation and impairs psychomotor performance for up to 5 hours, including vigilance, tracking, and subjective sleepiness 6.
- This sedative effect is potentiated by other CNS depressants including alcohol, benzodiazepines, and opioids 7.
- Consider using a non-sedating second-generation antihistamine (loratadine, desloratadine, levocetirizine, fexofenadine) instead of diphenhydramine for daytime use, as these show superior efficacy when combined with montelukast 3.
Montelukast Neuropsychiatric Warning
- FDA boxed warning (2020) alerts to potential neuropsychiatric events including agitation, depression, sleep disturbances, and suicidal thoughts/behaviors with montelukast 1.
- However, a large Swedish registry study of 74,291 children found no increased risk of neuropsychiatric adverse events compared to LABA users (HR 0.99; 95% CI 0.84-1.16) 8.
- Instruct patients to notify their physician if neuropsychiatric events occur while using montelukast 1.
- Age-stratified FAERS data suggest montelukast-associated fatality risk in suicide reports increases in adolescence but reverses after age 18 9.
Dosing Considerations
- Diphenhydramine: 25-50 mg orally as needed 5, 7.
- Montelukast: 10 mg once daily (adults/adolescents ≥15 years); 5 mg (6-14 years); 4 mg (2-5 years) 1.
- Both can be taken without regard to meals, though montelukast is typically dosed in the evening 1.
Clinical Algorithm
For patients requiring both medications:
- Verify indication: Confirm allergic rhinitis, asthma, or both conditions warrant dual therapy
- Assess sedation tolerance: If daytime alertness is critical (driving, operating machinery), substitute a non-sedating antihistamine for diphenhydramine
- Screen for psychiatric history: Exercise heightened caution with montelukast in patients with depression, anxiety, or suicidal ideation
- Educate patient: Warn about diphenhydramine sedation and montelukast neuropsychiatric monitoring
- Monitor response: Reassess symptom control in 2-4 weeks; consider stepping down if well-controlled for ≥3 months